This Form 144 filing serves as the required notice under Rule 144 of the Securities Act of 1933 for the proposed sale of restricted securities by an affiliate (director) of Rocket Lab USA Inc. Merline Saintil, a director, plans to sell 18,126 shares of common stock through Morgan Stanley Smith Barney LLC, representing a tiny fraction (about 0.003%) of the 567,445,449 shares outstanding. The shares were acquired via vesting of restricted stock under a registered compensation plan on June 14, 2023. The filing discloses prior sales by Saintil in the past three months totaling 37,500 shares: 15,000 on Dec 12, 2025 ($975,000), 5,000 on Dec 17 ($272,064.50), 5,000 on Dec 19 ($324,743.50), and 12,500 on Jan 14, 2026 ($1,124,368.50). Saintil certifies no knowledge of undisclosed material adverse information regarding Rocket Lab's operations.

This is a routine insider liquidity event from vested compensation shares, common for directors managing personal finances and tax obligations upon vesting, and does not signal underlying concerns given Saintil's certification of no material adverse information. The sale volume is immaterial relative to Rocket Lab's market cap and float, unlikely to impact stock price. Investors should monitor for continued selling patterns by Saintil or other insiders, quarterly insider transaction filings (Form 4s post-sale), and any correlation with business performance or stock price trends.